<DOC>
	<DOCNO>NCT02536092</DOCNO>
	<brief_summary>To evaluate safety efficacy Cutera excel HR dual wavelength 755nm Alexandrite 1064nm Nd : YAG laser hair removal .</brief_summary>
	<brief_title>A Prospective Multi-Center Study Novel Dual-Wavelength Laser Hair Removal</brief_title>
	<detailed_description>This multi-center prospective , open-label , uncontrolled multi-center study 50 male female subject , age 18 65 year , desire laser hair removal . Subjects receive 6 hair removal treatment , space 8 week apart , follow 12 week post-final treatment .</detailed_description>
	<mesh_term>Hypertrichosis</mesh_term>
	<criteria>Female Male , 18 65 year age ( inclusive ) . Fitzpatrick Skin Type I VI ( Appendix 3 ) . Subject black dark brown unwanted hair . Subject must able read , understand sign Informed Consent Form . Must willing able adhere treatment followup schedule posttreatment care instruction . Willing refrain shave treatment area 5 day prior study visit . Willing digital photograph take treatment area agree use photograph presentation , educational marketing purpose . Must agree use hair removal product , topical chemical depilatory , undergo hair removal procedure study , laser light therapy wax . Willing refrain excess sun exposure willing wear sunscreen treatment area study ( include followup period ) . Be good health , determine Investigator . Postmenopausal surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment entire course study Participation clinical trial another device drug within 6 month prior enrollment study . Had type professional hair removal procedure , laser , lightbased , RF electrolysis , treatment area within 12 month study participation . Had epilation treatment , wax mechanical epilator , treatment area within 6 month study participation . Subject show sign actinic bronze recent tan treatment area , unable/unlikely refrain tan study History malignant tumor target area . Pregnant and/or breastfeeding . Having infection , dermatitis rash treatment area . Significant concurrent illness , diabetes mellitus cardiovascular disease , e.g. , uncontrolled hypertension . Suffering coagulation disorder take prescription anticoagulation medication . History keloid scarring , hypertrophic scar abnormal wound healing . Currently use immunosuppressive medication history immunosuppression/immune deficiency disorder , psoriasis , eczema , vitiligo , systemic lupus erythematosus scleroderma . History seizure disorder due light . Any use medication know increase sensitivity light accord Investigator 's discretion . History disease stimulate heat , recurrent herpes simplex and/or herpes zoster ( shingle ) treatment area , unless treatment conduct follow prophylactic regimen History radiation treatment area undergo systemic chemotherapy treatment cancer . History pigmentary disorder , particularly tendency hyper hypopigmentation . Systemic use corticosteroid isotretinoin within 6 month study participation . Anytime life , use gold therapy ( gold salt ) disorder rheumatologic disease lupus . Excessively tanned area treat unable/unlikely refrain tan study . Current smoker history smoking within 6 month study participation . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>